Bleakley Financial Group LLC Acquires 24,649 Shares of Gilead Sciences, Inc. $GILD

Bleakley Financial Group LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 80.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 55,332 shares of the biopharmaceutical company’s stock after acquiring an additional 24,649 shares during the period. Bleakley Financial Group LLC’s holdings in Gilead Sciences were worth $7,712,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC lifted its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $25,000. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $26,000. Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.0%

Shares of NASDAQ:GILD opened at $130.04 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The stock has a market cap of $161.45 billion, a P/E ratio of 17.72 and a beta of 0.32. The business’s 50 day moving average is $129.72 and its 200 day moving average is $135.11. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,000 shares of company stock worth $9,978,740 over the last three months. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Truist Financial dropped their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Rothschild & Co Redburn reduced their price target on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Citigroup raised their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Morgan Stanley dropped their price objective on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Finally, Royal Bank Of Canada cut their price objective on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Twenty-six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $159.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.